23 Feb Avectas
Michael Maguire, Ph.D., CEO
April 21 | 10:15am | Gaudi 2 Ballroom
Avectas is a cell engineering technology business focused on improving the cost, manufacturing, and patient outcomes for the next generation of cellular therapies. Avectas has developed a unique cell engineering platform, SOLUPORE®, to enable the ex vivo manufacture of gene-modified cell therapy products. SOLUPORE® is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality. The SOLUPORE® technology is designed for use with mRNA and proteins, including gene-editing tools such as CRISPR. SOLUPORE® achieves excellent engineering efficiencies for delivery of these payloads to primary T cells for immuno-oncology and gene editing applications.